Asunto(s)
Enfermedad Injerto contra Huésped , Trasplante de Células Madre Hematopoyéticas , Síndrome de Stevens-Johnson , Enfermedad Injerto contra Huésped/diagnóstico , Enfermedad Injerto contra Huésped/etiología , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Humanos , Síndrome de Stevens-Johnson/diagnóstico , Síndrome de Stevens-Johnson/etiologíaRESUMEN
Coronary artery bypass grafting is a common surgical procedure that often uses the saphenous vein, internal thoracic artery, or radial artery as a conduit to improve blood circulation to the heart. When a blockage or impediment to arterial flow is noted, this procedure is undertaken to ensure the myocardium receives the blood it needs to function optimally. Infrequently, dermatoses overlying the conduit site may be observed, notably with the saphenous vein harvest site. Here we report the first case of sclerodermiform dermatitis occurring at the internal thoracic artery donor graft site. This unique case is important for providers to be aware of when evaluating a patient post-operatively who presents with new-onset dermatologic changes at the site of previous donor harvesting to ensure optimal treatment and management.
RESUMEN
Combination therapy with ipilimumab and nivolumab is an adjuvant treatment approach for metastatic melanoma that boasts increased 3-year survival when compared with a single immunotherapy agent. Combination therapy, however, is associated with increased toxicities, especially cutaneous side-effects. Here we present a patient with metastatic melanoma and a sudden eruption of painful nodules on the face and arms 10 days after the administration of the fourth dose of combination ipilimumab/nivolumab. Biopsies demonstrated lymphoid hyperplasia, not clinically or pathologically consistent with an infectious, malignant or autoimmune etiology; a diagnosis of pseudolymphoma secondary to ipilimumab/nivolumab was made. After a steroid taper, the lesions resolved, and the patient was restarted on nivolumab monotherapy 2 weeks later without recurrence of symptoms or disease.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Melanoma , Neoplasias Primarias Secundarias , Seudolinfoma , Neoplasias Cutáneas , Esteroides/administración & dosificación , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Humanos , Ipilimumab/administración & dosificación , Ipilimumab/efectos adversos , Masculino , Melanoma/tratamiento farmacológico , Melanoma/metabolismo , Melanoma/patología , Neoplasias Primarias Secundarias/tratamiento farmacológico , Neoplasias Primarias Secundarias/metabolismo , Neoplasias Primarias Secundarias/patología , Nivolumab/administración & dosificación , Nivolumab/efectos adversos , Seudolinfoma/inducido químicamente , Seudolinfoma/tratamiento farmacológico , Seudolinfoma/metabolismo , Seudolinfoma/patología , Neoplasias Cutáneas/tratamiento farmacológico , Neoplasias Cutáneas/metabolismo , Neoplasias Cutáneas/patología , Melanoma Cutáneo MalignoRESUMEN
Accurate and prompt diagnosis of skin ulcers is critical to optimise management; however, studies in hospitalised patients are limited. This retrospective review of dermatologic consultations included 272 inpatients with skin ulcers between July 2015 and July 2018 in four U.S. academic hospitals. The median age was 54 years and 45% were male. In 49.3% of the patients, skin ulcers were considered the primary reason for admission. Ulcers of 62% were chronic and 49.6% were located on the lower extremities. Pyoderma gangrenosum (17.3%), infection (12.5%), and exogenous causes (11.8%) were the leading aetiologies; 12% remained diagnostically inconclusive after consultation. Diagnostic agreements pre-dermatology and post-dermatology consult ranged from 0.104 (n = 77, 95% CI 0.051-0.194) to 0.553 (n = 76, 95% CI 0.440-0.659), indicating poor-modest agreement. This study highlights the diagnostic complexity and relative incidences of skin ulcers in the inpatient setting.
Asunto(s)
Úlcera Cutánea/epidemiología , Úlcera Cutánea/etiología , Adulto , Biopsia/estadística & datos numéricos , Dermatología , Femenino , Hospitalización , Hospitales Universitarios , Humanos , Masculino , Persona de Mediana Edad , Piodermia Gangrenosa/diagnóstico , Piodermia Gangrenosa/epidemiología , Derivación y Consulta , Estudios Retrospectivos , Enfermedades Cutáneas Infecciosas/diagnóstico , Enfermedades Cutáneas Infecciosas/epidemiología , Estados Unidos/epidemiologíaRESUMEN
Rosacea is a chronic inflammatory cutaneous disorder with an unclear pathogenesis. It has been associated with multiple comorbidities, including cardiovascular diseases, malignancies, depression, migraines, dementia, Parkinson disease, gastrointestinal disorders, and autoimmune conditions. The extent, clinical significance, and implications of these associations remain a topic of discussion. Further evaluation of these comorbidities may offer valuable insight for future screening practices and treatment recommendations.
Asunto(s)
Enfermedades Cardiovasculares/epidemiología , Enfermedades Gastrointestinales/epidemiología , Rosácea/epidemiología , Neoplasias Cutáneas/epidemiología , Enfermedades Autoinmunes/epidemiología , Comorbilidad , Depresión/epidemiología , Humanos , Trastornos Migrañosos/epidemiología , Enfermedades Neurodegenerativas/epidemiologíaAsunto(s)
Vendajes , Inmunoglobulinas Intravenosas/uso terapéutico , Esteroides/uso terapéutico , Síndrome de Stevens-Johnson/diagnóstico , Síndrome de Stevens-Johnson/terapia , Heridas y Lesiones/terapia , Femenino , Humanos , Masculino , Pronóstico , Medición de Riesgo , Índice de Severidad de la Enfermedad , Cuidados de la Piel/métodos , Cicatrización de Heridas/fisiologíaRESUMEN
Psoriatic arthritis (PsA) is a chronic, seronegative spondyloarthropathy associated with psoriasis (PsO). Treatment options range from non-pharmacologic measures to NSAIDS, DMARDs, and biologics, depending on patient presentation. Secukinumab (Cosentyx©) is a new biologic treatment option that was approved for use in treating adult patients with PsA in October 2016. Our paper explores the clinical trial evidence available for secukinumab to examine its safety and efficacy as a therapeutic agent for the treatment of PsA. While indirect comparisons of indicate that secukinumab is as effective as other treatment options, further studies directly comparing available treatments will be necessary to establish its place in treatment guidelines. As these and other trials are conducted, the evidence produced will further elucidate the clinical potential of secukinumab as a treatment option for patients with rheumatologic disease.
RESUMEN
Psoriasis has an enormous impact on patients' lives and is frequently associated with depression. Depression in psoriasis may be attributed, at least in part, to elevated proinflammatory cytokines rather than the psychosocial impact of psoriasis itself. Biologics that target inflammatory cytokines treat the clinical manifestations of psoriasis, but may also play a role in reducing associated depression. Multiple biologics have decreased symptoms of depression during clinical trials in psoriasis; however, these studies used a variety of depression screening tools, which limits comparison. Furthermore, it is difficult to distinguish whether improved depression is the result of the direct anti-inflammatory effect of the biologic, or the indirect effect of improved psoriasis leading to better psychological status. Future studies evaluating depression in patients with psoriasis could benefit from a standardized depression screening tool to mitigate discrepancies and facilitate comparison across treatment types. Here, we highlight the inflammatory overlap between psoriasis and depression by examining the pathophysiology of depression, and reviewing psoriasis clinical studies that assessed depression as an outcome measure.
Asunto(s)
Productos Biológicos/uso terapéutico , Citocinas/sangre , Depresión/psicología , Inflamación/psicología , Psoriasis/psicología , Antirreumáticos/uso terapéutico , Ensayos Clínicos como Asunto , Terapia Cognitivo-Conductual/métodos , Citocinas/metabolismo , Depresión/sangre , Depresión/etiología , Depresión/terapia , Humanos , Inflamación/sangre , Inflamación/etiología , Inflamación/terapia , Psoriasis/sangre , Psoriasis/etiología , Psoriasis/terapia , Resultado del TratamientoRESUMEN
INTRODUCTION: The incidence of adult acne is increasing worldwide. Despite clinical overlap with conventional acne, it has distinct features. Areas covered: A literature search of English-language review articles, randomized control studies and retrospective studies conducted over the past 30 years was performed using PubMed and Google Scholar. Search terms included acne, adult, topical medication, oral medication and skin of color. We highlight important clinical features and treatment modalities pertinent to the evaluation and management of adult acne. Given the relative dearth of literature detailing treatment options specific to adult acne, we offer expert opinion regarding management of the condition especially in special populations such as skin of color and pregnancy. Expert Opinion: It is unclear whether adult acne represents a distinct entity or a continuum of adolescent disease. Providers may opt to use topical medication as first-line, but should have a low threshold for switching to systemic therapy given the magnitude of psychosocial and emotional burden associated with the condition.
Asunto(s)
Acné Vulgar/tratamiento farmacológico , Antibacterianos/uso terapéutico , Anticonceptivos Orales Combinados/uso terapéutico , Fármacos Dermatológicos/uso terapéutico , Piel/efectos de los fármacos , Acné Vulgar/etiología , Acné Vulgar/microbiología , Acné Vulgar/psicología , Administración Cutánea , Administración Oral , Adulto , Antibacterianos/administración & dosificación , Anticonceptivos Orales Combinados/administración & dosificación , Fármacos Dermatológicos/administración & dosificación , Humanos , Calidad de Vida , Ensayos Clínicos Controlados Aleatorios como Asunto , Piel/efectos de la radiación , Resultado del Tratamiento , Terapia UltravioletaRESUMEN
BACKGROUND: Adjuvant treatment for early stage, estrogen receptor (ER) positive invasive breast cancer has been based on prognosticators such as menopausal status. The recurrence score (RS) from the 21-gene assay Oncotype DX (ODX) is predictive of a 10-y distant recurrence in this population but is rarely applied to premenopausal patients. The relationship between menopausal status and RS was evaluated. MATERIALS AND METHODS: An institutional review board-approved retrospective review was conducted of invasive breast cancer patients with known RS. ODX eligibility was based on National Comprehensive Cancer Network guidelines or physician discretion. Perimenopausal women were classified as premenopausal for statistical analyses. Comparisons of menopausal status and RS were made using general linear regression model and the exact Wilcoxon rank-sum test. RESULTS: Menopausal status was available for 575 patients (142 premenopausal, 433 postmenopausal). Median age was 46 y for premenopausal and 62 y for postmenopausal. Median invasive tumor size was 1.5 cm for both cohorts. Mastectomy rate was higher in the premenopausal group (54.8%) than postmenopausal (42%; P = 0.0001). Premenopausal women had a higher local-regional recurrence rate (2.8% versus 0%; P = 0.0384) but distant recurrence and overall survival were not statistically different (P = 0.6808). Median ER H-score was lower in premenopausal (H-score = 270) than postmenopausal women (H-score = 280; P < 0.0001). Median RS was 16 for both premenopausal (range, 0-54) and postmenopausal (range, 0-63) women. Menopausal status as a categorical variable was not predictive of RS (P-value = 0.6780). CONCLUSIONS: Menopausal status has limited predictive power for distant recurrence. Therefore, menopausal status alone should not preclude performance of ODX in ER-positive, early stage breast cancer.